<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PMJ</journal-id>
<journal-id journal-id-type="hwp">sppmj</journal-id>
<journal-id journal-id-type="nlm-ta">Palliat Med</journal-id>
<journal-title>Palliative Medicine</journal-title>
<issn pub-type="ppub">0269-2163</issn>
<issn pub-type="epub">1477-030X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269216311435269</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269216311435269</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sector-wide approach to phase III studies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hardy</surname><given-names>J</given-names></name>
<aff id="aff1-0269216311435269">Mater Health Services, Department of Palliative Care, Queensland, Australia</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
<aff id="aff2-0269216311435269">Discipline, Palliative and Supportive Services, Flinders University, South Australia, Australia</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269216311435269">Professor Janet Hardy, Mater Health Services, Department of Palliative Care, Queensland, Australia. Email: <email>Janet.Hardy@mater.org.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>6</issue>
<fpage>864</fpage>
<lpage>864</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>The European Association of Palliative Care is to be congratulated for systematically reviewing the literature on opioids for managing pain spanning topics from the treatment of opioid induced nausea and vomiting to whether one opioid is superior to another. The conclusion of most reviews was that ‘more research is needed’.</p>
<p>An anti-research culture exists within some hospice and palliative care services. ‘Gate keeping’ is common with patients left unaware of studies or actively discouraged from participating.<sup><xref ref-type="bibr" rid="bibr1-0269216311435269">1</xref></sup> Consequently, practice in palliative care is still based often on local clinicians’ preferences.</p>
<p>Some clinicians suggest that research is unethical in people at the end of life arguing that it places an excessive burden on patients and families. <italic>Not</italic> to perform research which has been sensitively designed for the population it invites to participate and whose sole aim is to systematically improve the quality of care for people at the end of life (where no other study population could answer the study question) is unethical. Use of medications outside registered indications is, in real terms, ad hoc experimentation almost always without the consent or knowledge of the patient.<sup><xref ref-type="bibr" rid="bibr2-0269216311435269">2</xref></sup> If a rigorously designed, adequately powered randomised controlled trial with clinical equipoise has been approved by a Research Ethics Committee, sanctioned by the national drug registration body and is recruiting at a site, the unethical behaviour is for clinicians at that site to use the study medication off label for that indication without patients’ knowledge.</p>
<p>People with advanced life-limiting illnesses are very willing to participate in research even if the findings from the study are only going to benefit other people in the future. People on study do better than those treated outside a trial even when assigned to the control arm, with evidence in another clinical discipline showing clinical outcomes in research-active centres will be significantly better than similar sites that do no research.<sup><xref ref-type="bibr" rid="bibr3-0269216311435269">3</xref></sup></p>
<p>Initiatives in Europe (European Palliative Care Research Collaborative),<sup><xref ref-type="bibr" rid="bibr4-0269216311435269">4</xref></sup> the United States of America (Palliative Care Research Collaborative)<sup><xref ref-type="bibr" rid="bibr5-0269216311435269">5</xref></sup> and Australia (Palliative Care Clinical Studies Collaborative)<sup><xref ref-type="bibr" rid="bibr6-0269216311435269">6</xref></sup> are systematically improving the evidence for prescribing at the end of life. It is time for the whole clinical community in hospice and palliative care to:</p>
<list id="list1-0269216311435269" list-type="simple">
<list-item><p>- acknowledge that care can be improved through generating and adopting best available evidence; and</p></list-item>
<list-item><p>- strongly support initiatives generating high-quality evidence for the populations we serve.</p></list-item>
</list>
<p>Adequate intervention studies designed to answer questions of fundamental importance to everyday practice are only possible with the collaboration of multiple sites. It is time for the whole sector to devote effort and resources to collaborative research networks to improve the care we offer.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0269216311435269">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>C</given-names></name>
<name><surname>Gilshenan</surname><given-names>K</given-names></name>
<name><surname>Hardy</surname><given-names>J</given-names></name>
</person-group>. <article-title>A survey of the views of palliative care healthcare professionals towards referring cancer patients to participate in randomized controlled trials in palliative care</article-title>. <source>Support Care Cancer</source> <year>2008</year>; <volume>16</volume>(<issue>12</issue>): <fpage>1397</fpage>–<lpage>1405</lpage>.</citation>
</ref>
<ref id="bibr2-0269216311435269">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
</person-group>. <article-title>Why don’t we do more rigorous clinical research so that we can stop experimenting on patients?</article-title> <source>J Pall Med</source> <year>2010</year>; <volume>13</volume>(<issue>6</issue>): <fpage>636</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr3-0269216311435269">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Majumdar</surname><given-names>SR</given-names></name>
<name><surname>Roe</surname><given-names>MT</given-names></name>
<name><surname>Peterson</surname><given-names>ED</given-names></name>
<etal/>
</person-group>. <article-title>Better outcomes for patients treated at hospitals that participate in clinical trials</article-title>. <source>Arch Intern Med</source> <year>2008</year>; <volume>168</volume>(<issue>6</issue>): <fpage>657</fpage>–<lpage>662</lpage>.</citation>
</ref>
<ref id="bibr4-0269216311435269">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaasa</surname><given-names>S</given-names></name>
</person-group>. <article-title>Palliative care research: time to intensify international collaboration</article-title>. <source>Palliat Med</source> <year>2008</year>; <volume>22</volume>(<issue>4</issue>): <fpage>301</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr5-0269216311435269">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abernethy</surname><given-names>AP</given-names></name>
<name><surname>Basch</surname><given-names>E</given-names></name>
<name><surname>Bull</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group</article-title>. <source>J Palliat Med</source> <year>2010</year>; <volume>13</volume>(<issue>12</issue>): <fpage>1407</fpage>–<lpage>1413</lpage>.</citation>
</ref>
<ref id="bibr6-0269216311435269">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Currow</surname><given-names>DC</given-names></name>
<name><surname>Shelby-James</surname><given-names>TM</given-names></name>
<name><surname>Agar</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations</article-title>. <source>J Support Care Cancer</source> <year>2010</year>; <volume>18</volume>(<issue>12</issue>): <fpage>1571</fpage>–<lpage>1578</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>